Back to catalogue
№ 055 36 filings · 2021-06-08 → 2026-05-06

B.P. MARSH & PARTNERS PLC

BPM
Financial Services Market cap £243m Overall fit 320 /1000

BPM is undervalued vs NAV with quality balance sheet and strong track record, but has effectively zero AI-receiver exposure (specialist insurance distribution holding company), modest operating leverage, and concentrated unquoted-asset risk. Right valuation, wrong theme for this investor's strategy.

Fair value range 815p–955p Mid case · £312m
Absolute upside +28.3% vs current market cap
Conviction 4/5 confidence in undervalued call
Supports the call
  • Multiple recent realisations at or above carrying value validate NAV (Paladin +38%, LPR +26%, SSRU substantial premium)
  • 11.1% annual NAV CAGR since 2006 flotation, accelerating in last 24 months
  • Debt-free balance sheet with £49.5m cash and clean accounting
Limits the call
  • Entire £271m equity book valued at Level 3 (unobservable inputs); softening insurance rates could compress multiples
  • Pantheon + XPT concentration ~48% of NAV creates idiosyncratic risk
Methodology

Discount-to-NAV with Level 3 portfolio fair value, validated by recent disposals

In one line · bull case

AIM-listed specialist insurance distribution investor trading at ~30% discount to a NAV repeatedly validated by realisations at premia, with a debt-free balance sheet and accelerating shareholder returns.

In one line · biggest risk

Softening insurance pricing cycle and concentration in two unquoted assets (Pantheon + XPT ~48% of NAV) could compress the Level 3 fair values that drive reported NAV.

Drivers
AI beneficiary 8 /100
No meaningful AI exposure; insurance brokers and MGAs are specialist distribution intermediaries with no proprietary data, software platform, or productivity moat captured by AI adoption.
Operating leverage 40 /100
Asset-light holding company with small central cost base, but absolute scale limits leverage; investee MGAs/brokers have moderate operating leverage on commission growth at the entity level.
Earnings vs expectations 75 /100
Consistently delivers or exceeds internal NAV growth targets; multiple disposals at premia to carry; SOP NAV-growth hurdles met by mid-2024.
Growth momentum 78 /100
NAV +42% in FY25 and continuing strongly through FY26; portfolio companies (Pantheon, XPT, ATC, SSRU) all growing 30–80% p.a.
Moat 50 /100
Brand and origination network in early-stage insurance investing is durable but execution-driven rather than structural; 67 inbound enquiries in FY26 reflects reputation.
Earnings quality 60 /100
Headline profit dominated by unrealised fair-value gains (Level 3) but recent disposals validate carrying values; cash conversion via dividends/loan interest is positive.
Management quality 80 /100
Long-tenured team with disciplined capital allocation, demonstrated patience in holding periods (avg 7 yrs), and proven ability to exit at premia.
Cyclicality 45 /100
Specialty insurance distribution shows moderate cyclicality through pricing cycles; current global rates softening but specialist segments more stable.
Leverage 5 /100
Net cash position with no Group borrowings; fortress balance sheet supports flexibility in any cycle.

I'll prepare the research note now based on the filings.

B.P. MARSH & PARTNERS PLC (BPM) — Investment Research Note

Executive summary

B.P. Marsh & Partners is a specialist AIM-listed minority-stake private equity investor in early-stage insurance distribution businesses (brokers and Managing General Agencies) globally, with a 35-year track record of identifying entrepreneurial management teams and crystallising value through trade sales. NAV has compounded at 11.1% p.a. since the 2006 IPO and accelerated dramatically — from £166.6m at Jan-2022 to £349.5m at Jul-2025 — driven by five major realisations (Kentro, Paladin/CBC, Lilley Plummer Risks, SSRU, Sterling) at large premia to carrying values, all of which validate the conservatism of the NAV. The single most important valuation fact today is that the £241.7m market cap implies a ~31% discount to the 31 July 2025 undiluted NAV of 956.1p per share — a wide discount that has been only partially closed despite a sustained pattern of management-led exits delivering double-digit and in some cases >85% IRRs.

Fair value estimate

Methodology: Discount-to-NAV approach, anchored on the most recent disclosed NAV of £349.5m (956.1p undiluted; 909.8p fully diluted) at 31 July 2025 2025-10 half-year. Several recent realisations occurred at or above carrying value (Paladin +38% vs Jul-23 carry; LPR +26% vs Jul-24 carry; Kentro at carry; Sterling at carry; SSRU at substantial premium), giving confidence the reported NAV is realisable and not aggressive.

  • Fair-value range: 815p – 955p per share
    • Low (15% discount to diluted NAV of 909.8p): ~775p
    • Mid (8% discount to diluted NAV): ~837p
    • High (at undiluted NAV of 956.1p): ~955p
  • Implied market-cap range: £283m – £349m (mid ~£305m)
  • vs current £241.7m mcap: absolute upside of ~17% to ~45%, mid case ~27%
  • A typical AIM specialist-investor discount-to-NAV is 10–20%, but BPM's track record of consistent NAV growth and crystallisation supports the tighter end. Applying a NAV-at-par exit for a control sale is not unreasonable given the demonstrated multi-decade NAV compounding.

Sector context

  • ICB classification confirmed: Financials / Financial Services.
  • Quality profile is above typical sector peers on net-cash balance sheet (debt-free since flotation), track record (11.1% annual NAV CAGR), and disclosure (transparent fair-value bridge, EBITDA multiples disclosed).
  • Listed peers: closest analogues are AIM-listed specialist financial-services investors (e.g. Tavistock Investments, Litigation Capital Management) and Lloyd's-aligned insurance investors. There is no perfect listed peer; portfolio companies sit alongside private peers like Howden, Ardonagh (which was itself a former shareholder), and Specialist Risk Group (a buyer of CBC).

Investment thesis

  1. Material discount to a NAV that has been repeatedly proven realisable. Five disposals since 2023 — Kentro at carry, Paladin at 38% premium, LPR at 26% premium, Sterling at carry, SSRU at substantial premium — demonstrate that the 956.1p NAV/share is conservative rather than aggressive 2025-02 trading update, 2025-10 half-year, 2026-02 trading update. Current 31% discount offers a margin of safety.

  2. Strong cash recycling and accelerating shareholder returns. £28m of dividends payable across FY26–FY28 (~8% of Jul-2025 NAV), plus £6.9m of buy-backs since 2023 2026-04 deferred consideration & special dividend. Capital allocation discipline is improving — historical aspiration to "cover expenses from yield" plus recent excess-realisation distributions.

  3. High-quality, diversified specialist insurance portfolio in a buoyant M&A market. The portfolio's two largest holdings — Pantheon Specialty (£105m / 30% of NAV at Jul-25) and XPT Group (£61m) — are both compounding revenues at 30–80% p.a. Insurance distribution M&A remains very active, providing exit optionality, and the £1.7bn aggregate GWP across the portfolio gives scale 2025-10 half-year.

Key risks

  1. Softening insurance rates and growing commoditisation. Global rates fell 7% in H1-2025; soft-cycle pressure could reduce commission growth at investee MGAs/brokers, compressing the multiples on which NAV is calculated 2025-10 half-year market commentary. The post-discount weighted-average EBITDA multiple is already 13.2x — modest valuation compression on the unquoted book has direct NAV consequences.

  2. Heavy concentration in two assets (Pantheon + XPT ≈ 48% of NAV). A reversal at either Pantheon (London casualty broker scaling from start-up in 2023 to a forecast £18m+ EBITDA in 2025) or XPT (US specialty platform with $1.2bn budgeted GWP) would materially impact NAV 2025-10 half-year.

  3. Founder/concert-party concentration restricts share buy-backs and creates governance dependency. The Brian Marsh concert party holds ~42% of voting rights, capping the Company's ability to buy back stock without triggering a Rule 9 mandatory offer — historically constraining the principal mechanism for closing the NAV discount 2025-10 half-year, 2025-06 final results.

Operating leverage

BPM is structurally an asset-light holding company: H1-2026 operating expenses of £4.9m supported income of £36.1m and a fair-value gain of £30.8m — i.e. the central cost base is ~£10m/year against a portfolio yielding £8m+ in dividends/fees/loan interest plus capital growth. The Group "covers expenses from portfolio yield" as a stated policy, and underlying pre-tax (excluding revaluation) was only £0.7m H1-2026, reflecting that the BPM holding company has limited inherent operating leverage — incremental fee/dividend income mostly drops through but the absolute scale is small relative to capital gains. Operating leverage at the investee level is more meaningful: MGAs and brokers have largely fixed-cost-base economics where commission growth (driven by rates and new producer hires) drops disproportionately to EBITDA. Pantheon scaling from start-up to £18m EBITDA in 2.5 years is the clearest example. A 10–20% revenue beat across the portfolio at this stage of the cycle would likely add ~£20–35m to NAV (mid-teens % uplift), not multiples [inferred from 2025-10 half-year financials].

Value-trap signals

  • Persistent discount to NAV despite a clean track record — partly explained by ~42% concert-party ownership reducing free float and the small AIM market cap.
  • Level 3 valuations only — entire £271m equity book is unobservable inputs valued by directors. However, multiple recent realisations at or above carrying value materially mitigates this. Not a structural value-trap signal in BPM's case.

Earnings vs expectations

The Group does not give EPS guidance or operate to analyst-consensus EPS — its key metric is NAV per share, and against this it has consistently delivered or exceeded its own stated growth targets. Aggregate dividends have been increased each year since FY23 (£0.9m → £2m → £8m → £13m planned). Disposals have repeatedly exceeded the most recently published carry value (Paladin +38%, LPR +26%, SSRU substantial premium), and the SOP option plan's 10% CAGR NAV growth threshold was achieved by Jul-2024 2024-10 half-year, 2025-06 final results, 2026-02 trading update. Pattern: consistent meet-or-beat versus internal targets across the past three years.

Conviction: 4 / 5 — high

Conviction drivers:

  • Multiple recent realisations at premia to carrying value provide independent validation of NAV.
  • Long, transparent track record (11.1% annual NAV compound since flotation; 13.1% since 1990).
  • Net-cash balance sheet and diversified portfolio limit downside.

Conviction caveats:

  • Level 3 valuations remain a structural uncertainty; cycle softening could compress multiples.
  • Two assets (Pantheon + XPT) drive nearly half the NAV — concentration risk.

Why this is a LOW fit for the investor's strategy (despite high conviction in fair value)

The investor's three explicit preferences are AI-receiver exposure, valuation discipline, and operating leverage. BPM scores strongly on valuation discipline but very poorly on AI exposure and only weakly on operating leverage. There is no AI-receiver angle in the portfolio — these are specialist insurance brokers, underwriting agencies, and one IFA. Even the Pantheon investment in Fraction (digital-asset insurance) is reinsurance for crypto, not AI infrastructure. Therefore, despite a clear ~25–30% upside to fair value and a quality balance sheet, BPM does not fit the investor's stated AI thesis and warrants a low overall score.

Filings consulted · 57

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-05-06Notice OF Results And Investor Presentation2026-05-06_9553647_notice-of-results-and-investor-presentation.md0.70
  2. 2026-04-16Deferred Consideration Receipt Amp Special Dividend2026-04-16_9522668_deferred-consideration-receipt-amp-special-dividend.md0.30
  3. 2026-02-24Trading Update2026-02-24_9443344_trading-update.md0.85
  4. 2026-01-21Interim Dividend Declaration2026-01-21_9370908_interim-dividend-declaration.md0.30
  5. 2025-12-15Special Dividend Declaration2025-12-15_9295762_special-dividend-declaration.md0.30
  6. 2025-10-21Half Year Results2025-10-21_9183082_half-year-results.md0.77
  7. 2025-10-07Notice OF HY Results And Investor Presentation2025-10-07_9155703_notice-of-hy-results-and-investor-presentation.md0.59
  8. 2025-09-23Trading Update2025-09-23_9124498_trading-update.md0.72
  9. 2025-08-07Result OF Secondary Placing2025-08-07_9033704_result-of-secondary-placing.md0.59
  10. 2025-08-06Proposed Secondary Placing2025-08-06_9032852_proposed-secondary-placing.md0.59
  11. 2025-07-17Result OF Agm2025-07-17_8985076_result-of-agm.md0.26
  12. 2025-06-24Notice OF Agm Correction2025-06-24_8945595_notice-of-agm-correction.md0.26
  13. 2025-06-24Notice OF Agm2025-06-24_8945337_notice-of-agm.md0.26
  14. 2025-06-10Final Results For The Year TO 31 January 20252025-06-10_8920566_final-results-for-the-year-to-31-january-2025.md0.85
  15. 2025-06-10Final Dividend Declaration2025-06-10_8921974_final-dividend-declaration.md0.26
  16. 2025-06-04Notice OF Annual Results And Investor Presentation2025-06-04_8912684_notice-of-annual-results-and-investor-presentation.md0.85
  17. 2025-05-09Result OF Secondary Placing2025-05-09_8870823_result-of-secondary-placing.md0.46
  18. 2025-05-08Proposed Secondary Placing2025-05-08_8868747_proposed-secondary-placing.md0.46
  19. 2025-04-16Special Dividend Declaration2025-04-16_8835300_special-dividend-declaration.md0.20
  20. 2025-02-24Trading Statement2025-02-24_8748413_trading-statement.md0.55
  21. 2025-01-23Interim Dividend Declaration2025-01-23_8701803_interim-dividend-declaration.md0.20
  22. 2024-10-23Half Year Results2024-10-23_8502624_half-year-results.md0.58
  23. 2024-10-09Notice OF HY Results And Investor Presentation2024-10-09_8475699_notice-of-hy-results-and-investor-presentation.md0.46
  24. 2024-09-17Trading Statement2024-09-17_8419669_trading-statement.md0.55
  25. 2024-07-23Result OF Agm2024-07-23_8326505_result-of-agm.md0.20
  26. 2024-06-27Notice OF Agm Amp Change OF Name OF Nomad And Broker2024-06-27_8283009_notice-of-agm-amp-change-of-name-of-nomad-and-broker.md0.39
  27. 2024-06-11Final Results For The Year TO 31 January 20242024-06-11_8252115_final-results-for-the-year-to-31-january-2024.md0.65
  28. 2024-03-25Completion OF Sale And Dividend Declaration2024-03-25_8103682_completion-of-sale-and-dividend-declaration.md0.14
  29. 2024-02-19Trading Update2024-02-19_8043384_trading-update.md0.38
  30. 2024-02-07Interim Dividend Declaration2024-02-07_8027114_interim-dividend-declaration.md0.14
  31. 2023-11-13Investee Company Update Disposal BY Lebc OF Aspira2023-11-13_7877096_investee-company-update-disposal-by-lebc-of-aspira.md0.34
  32. 2023-10-17Half Year Results2023-10-17_7820326_half-year-results.md0.41
  33. 2023-10-11Notice OF Half Year Results2023-10-11_7810710_notice-of-half-year-results.md0.41
  34. 2023-09-18Trading Statement2023-09-18_7760508_trading-statement.md0.38
  35. 2023-07-26Result OF Agm2023-07-26_7656958_result-of-agm.md0.14
  36. 2023-06-30Notice OF Agm2023-06-30_7604527_notice-of-agm.md0.14
  37. 2023-06-13Final Results2023-06-13_7571366_final-results.md0.45
  38. 2023-05-23Notice OF Annual Results And Investor Presentation2023-05-23_7539721_notice-of-annual-results-and-investor-presentation.md0.45
  39. 2023-02-14Trading Update2023-02-14_7451745_trading-update.md0.21
  40. 2023-01-16Interim Dividend Declaration And Share Buy Back2023-01-16_7436021_interim-dividend-declaration-and-share-buy-back.md0.07
  41. 2022-10-18Interim Results2022-10-18_7351311_interim-results.md0.23
  42. 2022-10-06Notice OF Interim Results Amp Investor Presentation2022-10-06_7250575_notice-of-interim-results-amp-investor-presentation.md0.23
  43. 2022-09-13Trading Update2022-09-13_7311817_trading-update.md0.21
  44. 2022-07-25Result OF Agm2022-07-25_7135829_result-of-agm.md0.07
  45. 2022-07-01Notice OF Agm2022-07-01_7153930_notice-of-agm.md0.07
  46. 2022-06-21Investor Presentation Change OF Date2022-06-21_7022539_investor-presentation-change-of-date.md0.17
  47. 2022-06-13Final Results2022-06-13_6937297_final-results.md0.25
  48. 2022-03-01Completion OF Disposal2022-03-01_6963694_completion-of-disposal.md0.19
  49. 2022-02-08Trading Update2022-02-08_6749145_trading-update.md0.21
  50. 2022-01-11Investee Company Disposal Summa Insurance2022-01-11_6807789_investee-company-disposal-summa-insurance.md0.19
  51. 2021-12-22Investee Company Disposal Walsingham Motor2021-12-22_6913209_investee-company-disposal-walsingham-motor.md0.19
  52. 2021-10-19Interim Results2021-10-19_6816734_interim-results.md0.23
  53. 2021-09-09Trading Statement2021-09-09_6772568_trading-statement.md0.21
  54. 2021-09-01Replacement Investee Company Disposal2021-09-01_6697146_replacement-investee-company-disposal.md0.19
  55. 2021-07-14Result OF Agm2021-07-14_6652078_result-of-agm.md0.07
  56. 2021-06-24Notice OF Agm2021-06-24_6781897_notice-of-agm.md0.07
  57. 2021-06-08Final Results2021-06-08_6619931_final-results.md0.25

This research note was authored by a large language model after reading 36 regulatory filings published between 2021-06-08 and 2026-05-06. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.